Search results for: Antibody
#39250147 
2024/09/09
To Up
Airway tryptase levels inform the lack of clinical efficacy of the tryptase inhibitor MTPS9579A in asthma.
Tryptase, a mast cell protease, has been identified as a potential therapeutic target in managing patients with refractory asthma. We assessed the efficacy, safety, pharmacokinetics, and pharmacodynamics of MTPS9579A, an anti-tryptase antibody, in a phase 2a randomized trial for patients with uncontrolled asthma and a phase 1c trial to understand activity within the lower respiratory tract.Horace Rhee, Lindsay M Henderson, Rebecca N Bauer, Kit Wong, Tracy L Staton, David F Choy, Prajna Banerjee, Victor Poon, Kenta Yoshida, Chen Chen, Keyi Long, Gizette Sperinde, Steven T Laing, Nicholas S Jones, Sara B Glickstein, Parul Dayal, Alice Fong, Ajit Dash, Grazyna Pulka, Brian Leaker, Dave Singh, Peter Bradding
2603 related Products with: Airway tryptase levels inform the lack of clinical efficacy of the tryptase inhibitor MTPS9579A in asthma.
11 set (5 x 1 ml)
Related Pathways
#39249645 2024/09/09
To Up
Three cases of relapsed eosinophilic sinusitis without eosinophilia during mepolizumab maintenance therapy for eosinophilic granulomatosis with polyangiitis.
We present three cases of eosinophilic granulomatosis with polyangiitis (EGPA) where patients experienced relapse of eosinophilic sinusitis without peripheral eosinophilia while on remission maintenance therapy with mepolizumab (MPZ), an anti-interleukin (IL)-5 monoclonal antibody. Despite the initial control of symptoms with high-dose prednisolone (PSL) and MPZ, patients experienced a relapse of nasal obstruction and eosinophilic infiltration in nasal mucosal biopsies. Notably, relapses occurred despite normal peripheral eosinophil counts, indicating the localized nature of eosinophilic inflammation. While IL-5 inhibitors effectively reduce peripheral blood eosinophils, eosinophilic sinusitis may persist due to local factors such as IL-4-mediated inflammation. IL-4 has been implicated in promoting eosinophil migration into nasal tissues, suggesting that IL-5 inhibitors alone may not sufficiently suppress eosinophilic infiltration in such cases. These findings highlight the importance of considering the possibility of eosinophilic sinusitis relapse in EGPA patients treated with IL-5 inhibitors and reduced glucocorticoid doses. Further research is warranted to elucidate the mechanisms underlying local eosinophilic inflammation and optimize treatment strategies for EGPA patients.Kazuma Nishisaka, Yo Ueda, Mie Inoue, Masaaki Ishikawa, Goichi Kageyama, Jun Saegusa
1229 related Products with: Three cases of relapsed eosinophilic sinusitis without eosinophilia during mepolizumab maintenance therapy for eosinophilic granulomatosis with polyangiitis.
500 ml
Related Pathways
#39249633 2024/09/09
To Up
Diagnostic performance of 2-[F]FDG PET/CT in recurrent differentiated thyroid cancer and elevated antithyroglobulin antibodies: an updated systematic review and bivariate meta-analysis.
This updated systematic review and bivariate meta-analysis aimed to investigate the diagnostic performance of 2-[F]FDG PET/CT for the detection of recurrent disease in patients with differentiated thyroid cancer (DTC) who have negative I whole body scintigraphy and increased antithyroglobulin antibodies (TgAb) levels.Domenico Albano, Arnoldo Piccardo, Alessio Rizzo, Marco Cuzzocrea, Gianluca Bottoni, Pietro Bellini, Francesco Bertagna, Giorgio Treglia
2496 related Products with: Diagnostic performance of 2-[F]FDG PET/CT in recurrent differentiated thyroid cancer and elevated antithyroglobulin antibodies: an updated systematic review and bivariate meta-analysis.
1000 TESTS/0.65ml2 Pieces/Box0.1 mg100 μg1 ml100 μg100 μg100 μg250 TESTS
Related Pathways
#39249605 2024/09/09
To Up
Adjuvant chemoradiotherapy plus pembrolizumab for locally advanced esophageal squamous cell carcinoma with high risk of recurrence following neoadjuvant chemoradiotherapy: a single-arm phase II study.
Adjuvant nivolumab reduces recurrence in patients with locoregional esophageal cancer who had pathological residual disease after neoadjuvant chemoradiotherapy and R0 resection. However, the efficacy of adjuvant anti-PD-1 therapy in patients at higher risk of recurrence remains unclear.Jhe-Cyuan Guo, Ta-Chen Huang, Hung-Yang Kuo, Chia-Chi Lin, Feng-Ming Hsu, Jason Chia-Hsien Cheng, Yen-Lin Huang, Min-Shu Hsieh, Pei-Ming Huang, Jang-Ming Lee, Shu-Ling Wu, Chih-Hung Hsu
2523 related Products with: Adjuvant chemoradiotherapy plus pembrolizumab for locally advanced esophageal squamous cell carcinoma with high risk of recurrence following neoadjuvant chemoradiotherapy: a single-arm phase II study.
Related Pathways
#39249581 2024/09/09
To Up
The efficacy of rituximab in the treatment of IgA vasculitis nephritis.
The utility of Rituximab (RTX) for IgA vasculitis nephritis (IgAVN) is not well established. Up to now, we analysed the largest samples of IgAVN patients treated by RTX with a total of 41 retrieved subjects up to December 29, 2023 in the present systematic review. We assessed the clinical profiles, efficacy, and safety of RTX treatments. The present review showed that the renal function tended to be stabilized (P = 1.000) and urinalysis tended to normalize after RTX treatment with no serious adverse events reported. Moreover, 40% (16/40) of patients was freed use of glucocorticoid after RTX administration (P < 0.001). The remission rate was 92.7% (38/41) and complete remission rate was 46.3% (19/41) in IgAVN patients. Interestingly, 76.9% (10/13) of IgAVN child patients achieved complete remission when compared with 32.1% (9/28) of adult patients (P = 0.017). In summary, our results support the benefit of RTX therapy in IgAVN patients, especially children subjects.Yi Xiong, Santiago Cuevas, Gaosi Xu, Honghong Zou
2826 related Products with: The efficacy of rituximab in the treatment of IgA vasculitis nephritis.
112
Related Pathways
#39249542 2024/09/09
To Up
Modest survival benefits of autologous stem cell transplantation in multiple myeloma with renal impairment: a critical appraisal of the pre-antibody era.
The benefit of high-dose melphalan followed by autologous hematopoietic stem cell transplantation (HDM-ASCT) for multiple myeloma (MM) patients with renal insufficiency (RI) is debated. A systematic review and meta-analysis were conducted to assess the safety and efficacy of HDM-ASCT in MM patients with RIs, and the findings were compared with real-world data. The study included 26 articles, 13 of which were pooled for meta-analysis. We compared three different types of MM patients with RI against MM patients with normal renal function (NRF). These patients were: MM patients with RI at the time of transplantation; MM patients with RI at the time of diagnosis; MM patients with RI at diagnosis but with NRF at transplantation. The meta-analysis indicated that MM patients with RIs conditioned with melphalan ≤ 140 mg/m followed by ASCT had transplant-related mortality rates comparable to those without RIs. The complete response rates post-ASCT were similar between MM patients with RIs and those with NRF. Although progression-free survival (PFS) was statistically similar between the groups, MM patients with RIs had significantly poorer overall survival (OS) than those with NRF. The real-world data supported these findings. With a reduced dose of melphalan, ASCT is safe and effective for MM patients with RI. MM patients with RI have similar complete response rates and PFS after ASCT compared to MM patients with NRF. The lower OS in MM patients with RI indicates the need for further research to improve OS in these patients.Yan Li, Xinyi Zhang, Zhongqing Zou, Yanqiu Xiong, Xinyuan Gu, Ruiji Zou, Jing Tan, Li Zhang, Yuhuan Zheng, Ting Niu
1789 related Products with: Modest survival benefits of autologous stem cell transplantation in multiple myeloma with renal impairment: a critical appraisal of the pre-antibody era.
16 Arrays/Slide100ug Lyophilized100ug Lyophilized100ug Lyophilized16 Arrays/Slide100ug Lyophilized100ug Lyophilized100ug Lyophilized
Related Pathways
#39249502 2024/09/09
To Up
Exploring autoimmune endocrine diseases induced by monoclonal antibodies used as multiple sclerosis pharmacotherapy: a systematic review.
Multiple sclerosis (MS) is an autoimmune neurodegenerative disease that targets myelin, leading to inflammation and neuron death. Monoclonal antibodies (MAb) have long been used to control the progression and exacerbations of this disorder, which may induce secondary autoimmune disease as a rare adverse event. This systematic review aimed to gather data of case reports around this subject and to explain the mechanism behind their occurrence. PubMed, Scopus, and Google scholar were searched for published case reports until February 21st 2024. The Joanna Briggs Institute (JBI) critical appraisal checklist was used to assess the quality of the included studies. In total, 20 articles met the inclusion criteria and were reviewed by the authors. The most autoimmune disorders were thyroiditis and as expected induced by alemtuzumab. Ocrelizumab had one secondary autoimmune complication reported. MAbs used in MS immunotherapy have shown to induce secondary autoimmune disorders including endocrine complications, which have been reported in many case reports. It is recommended to use these agents with caution and monitor patients for symptoms of the aforementioned conditions.Mohammad Ali Sahraian, Shahaboddin Emami, Sara Ataei, Nasibeh Ghalandari
2159 related Products with: Exploring autoimmune endocrine diseases induced by monoclonal antibodies used as multiple sclerosis pharmacotherapy: a systematic review.
200 ug1 mg1 mg100.00 ug100.00 ug500 ug1 mg100.00 ug100.00 ug1 mg200 ug100 ug
Related Pathways
#39249490 2024/09/09
To Up
ImmunoPET imaging of EpCAM in solid tumours with nanobody tracers: a preclinical study.
Epithelial cell adhesion molecule (EpCAM) is a potential therapeutic target and anchoring molecule for circulating and disseminated tumour cells (CTC/DTC) in liquid biopsy. In this study, we aimed to construct EpCAM-specific immuno-positron emission tomography (immunoPET) imaging probes and assess the diagnostic abilities in preclinical cancer models.Dongsheng Xu, You Zhang, Wei Huang, Xinbing Pan, Shuxian An, Cheng Wang, Gang Huang, Jianjun Liu, Weijun Wei